Table 2—

Macrovascular outcomes in early- and usual-onset type 2 diabetic patients and in age- and sex-matched control subjects

VariableEarly-onset
Usual onset
Type 2 diabetic patientsControl subjectsHR (95% CI)*Type 2 diabetic patientsControl subjectsHR (95% CI)*
n1,6001,6006,2446,244
MI pre/at diagnosis (%)0.80.413.07.3
MI after diagnosis (%)4.61.214.0 (6.2–31.4)23.412.23.7 (3.2–4.2)
Stroke pre/at diagnosis (%)0.30.33.72.3
Stroke after diagnosis (%)1.60.630.1 (6.0–152.1)11.16.53.1 (2.7–3.7)
CABG pre/at diagnosis (%)000.50.5
CABG after diagnosis (%)0.80.23.82.03.1 (2.5–4.0)
PTCA pre/at diagnosis (%)0.100.30.1
PTCA after diagnosis (%)1.00.36.5 (2.1–20.3)1.91.13.5 (2.5–5.0)
PVD pre/at diagnosis (%)0.30.12.11.3
PVD after diagnosis (%)1.60.83.6 (1.7–7.9)9.14.04.2 (3.5–5.1)
Any macrovascular complication§ pre/at diagnosis (%)1.30.716.29.5
Any macrovascular complication§ after diagnosis (%)7.02.57.9 (4.8–13.0)34.318.53.8 (3.4–4.2)
  • * HRs are obtained from Cox proportional hazards model and adjusted for sex and length of follow-up. Only subjects who did not have the complication at diagnosis are included in the analyses.

  • 95% CIs do not overlap between early- and usual-onset groups.

  • Due to small number of CABG events in control subjects, HR can not be calculated.

  • § Any macrovascular event is any of the above complications.